BAIBYS Fertility

BAIBYS™ develops an AI and robotics based COMPLETELY AUTONOMOUS system for sperm selection for IVF, which will improve success rates, reduce birth defects, and raise clinics’ revenue According to the WHO guidelines, 96% of the sperm cells of a healthy man are abnormal. Natural fertilization overcomes this problem by having millions of sperm cells compete on one egg through various selection processes such that only the best one wins. However, in IVF today, the injected sperm cells are selected arbitrarily. Thus, the natural sperm selection process is bypassed, leading to fewer successful pregnancies and more birth defects. A manual selection at high magnification was proposed, showing higher success rates and reduced birth defects (NEJM, 2001). Nevertheless, this manual procedure was not widely adopted since it was lengthy (3h vs. a few min.), subjective and inconsistent, required extensive training, and was therefore expensive. BAIBYS’ system performs the same selection process, based on the same well-accepted criteria, COMPLETELY AUTONOMOUSLY, in a fraction of the time and cost of the current manual process. The user needs only to place a cartridge with the sperm sample into the console and press a button, and the system will autonomously identify the optimal cells and will robotically transfer them to a separate droplet in the cartridge. Eliminating the drawbacks of the manual process by making it fast, objective, consistent, without trained personnel, and affordable, would allow its use in every IVF cycle, improving success rates, and reducing birth defects, while raising the clinics’ throughput and reputation. The system shall revolutionize the IVF process by reducing the financial and emotional crisis involved with it by saving failed IVF treatments, reducing the economic burden on health systems, raising IVF clinics throughput, making IVF more accessible globally, and most importantly, reducing birth defects and helping more families in having healthy BAIBYS™

BAIBYS Fertility has raised $7M in total funding across 5 rounds. The company is currently at the A stage. Key investors include Firstime VC, ROHTO, 4T Ventures.

BAIBYS Fertility was founded in 2020 by Gal Golov (Co-Founder & Co-CEO), Nino Guy Cassuto (CMO).

BAIBYS Fertility operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Machinery & Robotics, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

BAIBYS Fertility is based in HaBarzel St 26, Tel Aviv-Yafo, Israel, Center District.